A detailed history of Ruffer LLP transactions in Exelixis, Inc. stock. As of the latest transaction made, Ruffer LLP holds 46,500 shares of EXEL stock, worth $1.94 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
46,500
Previous 81,696 43.08%
Holding current value
$1.94 Million
Previous $3.37 Million 42.62%
% of portfolio
0.11%
Previous 0.23%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 28, 2026

SELL
$34.54 - $43.59 $1.22 Million - $1.53 Million
-35,196 Reduced 43.08%
46,500 $1.94 Million
Q3 2025

Nov 03, 2025

BUY
$36.22 - $46.25 $195,080 - $249,102
5,386 Added 7.06%
81,696 $3.37 Million
Q2 2025

Jul 16, 2025

SELL
$34.13 - $46.26 $1.5 Million - $2.03 Million
-43,894 Reduced 36.52%
76,310 $3.36 Million
Q1 2025

May 09, 2025

BUY
$32.38 - $39.16 $305,893 - $369,944
9,447 Added 8.53%
120,204 $4.44 Million
Q4 2024

Feb 07, 2025

BUY
$25.39 - $36.46 $2.81 Million - $4.04 Million
110,757 New
110,757 $3.69 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $13.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Ruffer LLP Portfolio

Follow Ruffer LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ruffer LLP, based on Form 13F filings with the SEC.

News

Stay updated on Ruffer LLP with notifications on news.